Chapter 3.II: XEVPRM detailed user guidance on the electronic submission of information on medicinal products for human use by marketing authorisation holders to the EMA

Submitted by Anonymous (not verified) on 9 September 2026 - 14:20

Chapter 3.II: XEVPRM detailed user guidance on the electronic submission of information on medicinal products for human use by marketing authorisation holders to the EMA

2026 annual open meeting of the European Network of Paediatric Research at EMA (EnprEMA), Online, European Medicines Agency, Amsterdam, the Netherlands, from 5 November 2026, 09:00 (CET) to 5 November 2026, 16:30 (CET)

Submitted by Anonymous (not verified) on 9 September 2026 - 10:00

2026 annual open meeting of the European Network of Paediatric Research at EMA (EnprEMA), Online, European Medicines Agency, Amsterdam, the Netherlands, from 5 November 2026, 09:00 (CET) to 5 November 2026, 16:30 (CET)

Guidelines on good pharmacovigilance practices (GVP): Introductory cover note, last updated with revision 2 of Module III on pharmacovigilance inspections

Submitted by Anonymous (not verified) on 9 September 2026 - 7:44

Guidelines on good pharmacovigilance practices (GVP): Introductory cover note, last updated with revision 2 of Module III on pharmacovigilance inspections

Human medicines European public assessment report (EPAR): Benlysta, belimumab, Date of authorisation: 13/07/2011, Revision: 41, Status: Authorised

Submitted by Anonymous (not verified) on 8 September 2026 - 16:32

Human medicines European public assessment report (EPAR): Benlysta, belimumab, Date of authorisation: 13/07/2011, Revision: 41, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More
randomness